Disease State Network Year-in-Review: Thyroid

Friday, May 13, 2022

3:00 PM – 4:00 PM

Location: Breakout Room 5-Aqua DEF (Level 3)

Speaker(s)

Benjamin J. Gigliotti, MD
Assistant Professor of Medicine
University of Rochester
Rochester, New York, United States

Disclosure: Blueprint Medicines (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- RET+ Virtual Thyroid Discussion Forum (a 7-hour advisory board commitment), started 3/3/21, ended 3/17/21)

PDF Slides
Alex Tessnow, MD
Associate Professor
University of Texas Southwestern Medical Center
Southlake, Texas, United States

Disclosure: Horizon (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Spectrix Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

PDF Slides

Learning Objectives:

Analyze recent trends regarding hypothyroid management in the United States and explore recent data directly comparing T4 monotherapy vs T3/T4 combination therapy in hypothyroid patients with persistent symptoms despite normal TSH.
Introduce the concept of statins in conjunction with IV glucocorticoids in the treatment of Graves eye disease.
Summarize recent data informing management for the thyroid cancer risk spectrum, including conservative approaches for low-risk disease and increasing therapeutic options for patients with advanced disease.

Participants should be aware of the following financial/non-financial relationships:

Benjamin J. Gigliotti, MD: Blueprint Medicines (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)

Alex Tessnow, MD: Horizon (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Spectrix Therapeutics (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)